卡培立肽

卡培立肽用途

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine 是一种含 28 个氨基酸的激素,由心脏产生并分泌,以响应心脏损伤和机械拉伸。ANP (1-28) 抑制内皮素-1 (endothelin-1) 分泌。

卡培立肽名称

[ CAS 号 ]:
89213-87-6

[ 中文名 ]:
卡培立肽

[ 英文名 ]:
Atrial Natriuretic Factor (1-28) (human) acetate salt

[中文别名 ]:

人重组型α-心房尿钠肽

[英文别名 ]:

Atrial natriuretic peptide (human, 1-28)
α-Humanatrial natriuretic peptide
ANP1-28,HUMAN
HSCH2CH2(NHCO)2(CH2)2CH(CH3)2
α-ANF (1-28), human
Atrial natriuretic peptide-28 (human)
carperitide
(1-28)-Human atrial natriuretic peptide
Atrial Natriuretic Peptide (1-28), human

卡培立肽生物活性

[ 描述 ]:

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 内皮素受体

多肽产品

研究领域 >> 心血管疾病

[ 靶点 ]

Endothelin-1[1]

[体外研究]

心房利钠肽(ANP)是最初从哺乳动物心脏分离的利尿剂,利尿钠和血管舒张肽激素。在培养的猪内皮细胞中,用血管紧张素II(Ang II)刺激后猪ANP(1-28)对免疫反应性内皮素-1分泌的抑制与细胞cGMP水平的增加相平行。猪ANP(1-28)在用Ang II刺激后强烈抑制猪主动脉中的免疫反应性内皮素-1分泌[1]。 ANP是一种参与电解质和液体稳态的心脏激素。使用培养的人脐静脉内皮细胞,ANP抑制由血管紧张素II(ANGII)和凝血酶刺激的内皮素-1分泌。人ANP(1-28)抑制免疫反应性(ir)-内皮素-1分泌并增加人脐静脉内皮细胞中的环GMP [2]。在来自正常大鼠的肾小球中,人125I-ANP(1-28)结合单个高亲和力受体群,平均平衡解离常数为0.46nM。人ANP(1-28)以高亲和力刺激的cGMP积累与肾小球ANP受体结合。人ANP(1-28)显着刺激cGMP的产生,但在正常大鼠肾小球中不产生cAMP [3]。

[参考文献]

[1]. Kohno M, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 1992 Feb;70(2):241-7.

[2]. Kohno M, et al. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest. 1991 Jun;87(6):1999-2004.

[3]. Ballermann BJ, et al. Physiologic regulation of atrial natriuretic peptide receptors in rat renal glomeruli. J Clin Invest. 1985 Dec;76(6):2049-56.

[相关活性小分子]

卡培立肽物理化学性质

[ 密度 ]:
1.6±0.1 g/cm3

[ 分子式 ]:
C₁₂₇H₂₀₃N₄₅O₃₉S₃

[ 分子量 ]:
3080.444

[ 精确质量 ]:
3078.444580

[ PSA ]:
1479.28000

[ LogP ]:
-14.30

[ 折射率 ]:
1.689

[ 储存条件 ]:
-20°C，密闭，干燥

卡培立肽毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CJ9920000

CHEMICAL NAME :: Atriopeptin-33(rat), 1-de-L-leucine-2-de-L-alanine-3-deglycine-4-de-L-prol ine-5-de-L-arginine-1 7-L-methionine-

CAS REGISTRY NUMBER :: 89213-87-6

LAST UPDATED :: 199406

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: Cl27-H203-N45-O39-S3

MOLECULAR WEIGHT :: 2512.81

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 110 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - behavioral

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 44,495,1992

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 840 mg/kg

SEX/DURATION :: male 9 week(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 44,485,1992